Wyatt Calypso Succeeds in ABRF-MIRG Study
News Apr 29, 2013
The conclusions of the 2012 MIRG study were announced at the ABRF 2013 annual meeting in Palm Springs earlier this month.
In the study, a pair of unknown proteins, prepared and characterized by the ABRF, was sent out to multiple labs to determine affinity and stoichiometry of binding. In a single afternoon consisting of 2 CG-MALS runs, the Wyatt Calypso system correctly determined that one molecule of Protein Y (26.3 kDa) binds 2 molecules of Protein X (11.9 kDa), one with KD of 10 nM and the other with 14 µM. This analysis agreed perfectly with the extensive AUC and ITC measurements performed by ABRF prior to distributing the samples.
The CG-MALS measurement was the only solution-based measurement among the participating labs. The others used surface plasmon resonance (SPR) instruments which require immobilization of one of the binding partners. Only 4 of 13 SPR labs correctly measured and interpreted the data, typically taking 1-2 days even though the chip immobilization recipe and regeneration were provided by the organizers.
Interestingly, the affinities determined by SPR were significantly weaker than those found by any of the solution-based measurements (AUC, ITC, CG-MALS), indicating that, in this instance, immobilization modifies the interaction.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018